Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Prostate Cancer

  Free Subscription


Articles published in Cancer Lett

Retrieve available abstracts of 67 articles:
HTML format



Single Articles


    March 2024
  1. KANAOKA S, Okabe A, Kanesaka M, Rahmutulla B, et al
    Chromatin activation with H3K36me2 and compartment shift in metastatic castration-resistant prostate cancer.
    Cancer Lett. 2024;588:216815.
    PubMed     Abstract available


  2. RODRIGO-FAUS M, Vincelle-Nieto A, Vidal N, Puente J, et al
    CRISPR/Cas9 screenings unearth protein arginine methyltransferase 7 as a novel essential gene in prostate cancer metastasis.
    Cancer Lett. 2024 Mar 1:216776. doi: 10.1016/j.canlet.2024.216776.
    PubMed     Abstract available


    February 2024
  3. WEI Z, Zhang C, Song Y, Han D, et al
    CircUBE3A(2,3,4,5) promotes adenylate-uridylate-rich binding factor 1 nuclear translocation to suppress prostate cancer metastasis.
    Cancer Lett. 2024 Feb 27:216743. doi: 10.1016/j.canlet.2024.216743.
    PubMed     Abstract available


  4. YIN W, Chen G, Li Y, Li R, et al
    Identification of a 9-gene signature to enhance biochemical recurrence prediction in primary prostate cancer: A benchmarking study using ten machine learning methods and twelve patient cohorts.
    Cancer Lett. 2024 Feb 21:216739. doi: 10.1016/j.canlet.2024.216739.
    PubMed     Abstract available


  5. CHEN H, Dong K, Ding J, Xia J, et al
    CRISPR genome-wide screening identifies PAK1 as a critical driver of ARSI cross-resistance in prostate cancer progression.
    Cancer Lett. 2024 Feb 14:216725. doi: 10.1016/j.canlet.2024.216725.
    PubMed     Abstract available


  6. ZHAO G, Forn-Cuni G, Scheers M, Lindenbergh PP, et al
    Simultaneous targeting of AMPK and mTOR is a novel therapeutic strategy against prostate cancer.
    Cancer Lett. 2024 Feb 7:216657. doi: 10.1016/j.canlet.2024.216657.
    PubMed     Abstract available


    January 2024
  7. SAEZ-MARTINEZ P, Porcel-Pastrana F, Montero-Hidalgo AJ, Lozano de la Haba S, et al
    Dysregulation of RNA-Exosome machinery is directly linked to major cancer hallmarks in prostate cancer: Oncogenic role of PABPN1.
    Cancer Lett. 2024 Jan 18:216604. doi: 10.1016/j.canlet.2023.216604.
    PubMed     Abstract available


    November 2023
  8. ALSAMRAAE M, Costanzo-Garvey D, Teply BA, Boyle S, et al
    Androgen receptor inhibition suppresses anti-tumor neutrophil response against bone metastatic prostate cancer via regulation of TbetaRI expression.
    Cancer Lett. 2023 Nov 6:216468. doi: 10.1016/j.canlet.2023.216468.
    PubMed     Abstract available


    October 2023
  9. WANG C, Wang T, Li KJ, Hu LH, et al
    SETD4 inhibits prostate cancer development by promoting H3K27me3-mediated NUPR1 transcriptional repression and cell cycle arrest.
    Cancer Lett. 2023 Oct 23:216464. doi: 10.1016/j.canlet.2023.216464.
    PubMed     Abstract available


    September 2023
  10. SLOOTBEEK PHJ, Overbeek JK, Ligtenberg MJL, van Erp NP, et al
    PARPing up the right tree; an overview of PARP inhibitors for metastatic castration-resistant prostate cancer.
    Cancer Lett. 2023 Sep 7:216367. doi: 10.1016/j.canlet.2023.216367.
    PubMed     Abstract available


    August 2023
  11. NADERINEZHAD S, Zhang G, Wang Z, Zheng D, et al
    A novel GRK3-HDAC2 regulatory pathway is a key direct link between neuroendocrine differentiation and angiogenesis in prostate cancer progression.
    Cancer Lett. 2023 Aug 3:216333. doi: 10.1016/j.canlet.2023.216333.
    PubMed     Abstract available


    July 2023
  12. WANG F, Liu S, Liu F, Xu T, et al
    TIGIT immune checkpoint blockade enhances immunity of human peripheral blood NK cells against castration-resistant prostate cancer.
    Cancer Lett. 2023;568:216300.
    PubMed     Abstract available


    May 2023
  13. GAO K, Li X, Ni J, Wu B, et al
    Non-coding RNAs in enzalutamide resistance of castration-resistant prostate cancer.
    Cancer Lett. 2023 May 30:216247. doi: 10.1016/j.canlet.2023.216247.
    PubMed     Abstract available


  14. ZHANG Y, Fan A, Li Y, Liu Z, et al
    Single-cell RNA sequencing reveals that HSD17B2 in cancer-associated fibroblasts promotes the development and progression of castration-resistant prostate cancer.
    Cancer Lett. 2023 May 25:216244. doi: 10.1016/j.canlet.2023.216244.
    PubMed     Abstract available


  15. WILLIAMS A, Gutgesell L, de Wet L, Selman P, et al
    SOX(2) expression in prostate cancer drives resistance to nuclear hormone receptor signaling inhibition through the WEE1/CDK1 signaling axis.
    Cancer Lett. 2023 May 9:216209. doi: 10.1016/j.canlet.2023.216209.
    PubMed     Abstract available


    April 2023
  16. HAN H, Li H, Ma Y, Zhao Z, et al
    Monoamine oxidase A (MAOA): A promising target for prostate cancer therapy.
    Cancer Lett. 2023 Apr 17:216188. doi: 10.1016/j.canlet.2023.216188.
    PubMed     Abstract available


    December 2022
  17. SU S, You S, Wang Y, Tamukong P, et al
    PAK4 inhibition improves PD1 blockade immunotherapy in prostate cancer by increasing immune infiltration.
    Cancer Lett. 2022 Dec 9:216034. doi: 10.1016/j.canlet.2022.216034.
    PubMed     Abstract available


    November 2022
  18. FENG J, Xi Z, Jiang X, Li Y, et al
    Saikosaponin a enhances Docetaxel efficacy by selectively inducing death of dormant prostate cancer cells through excessive autophagy.
    Cancer Lett. 2022 Nov 25:216011. doi: 10.1016/j.canlet.2022.216011.
    PubMed     Abstract available


  19. LACOMBE L, Hovington H, Brisson H, Mehdi S, et al
    UGT2B28 accelerates prostate cancer progression through stabilization of the endocytic adaptor protein HIP1 regulating AR and EGFR pathways.
    Cancer Lett. 2022 Nov 4:215994. doi: 10.1016/j.canlet.2022.215994.
    PubMed     Abstract available


    October 2022
  20. CHUA CW, Kruithof-de Julio M
    Exploring prostate cancer in the post-genomic era.
    Cancer Lett. 2022;553:215992.
    PubMed     Abstract available


    September 2022
  21. LIU J, Dong L, Zhu Y, Dong B, et al
    Prostate cancer treatment - China's perspective.
    Cancer Lett. 2022 Sep 23:215927. doi: 10.1016/j.canlet.2022.215927.
    PubMed     Abstract available


  22. FERGUSON AM, Rubin MA
    Lineage plasticity in prostate cancer: Looking beyond intrinsic alterations.
    Cancer Lett. 2022 Sep 5:215901. doi: 10.1016/j.canlet.2022.215901.
    PubMed     Abstract available


    August 2022
  23. JIAO J, Zhang J, Li Z, Wen W, et al
    Prostate specific membrane antigen positron emission tomography in primary prostate cancer diagnosis: First-line imaging is afoot.
    Cancer Lett. 2022 Aug 23:215883. doi: 10.1016/j.canlet.2022.215883.
    PubMed     Abstract available


    July 2022
  24. ZHANG J, Li S, Zhang J, Zhang W, et al
    Docetaxel resistance-derived LINC01085 contributes to the immunotherapy of hormone-independent prostate cancer by activating the STING/MAVS signaling pathway.
    Cancer Lett. 2022 Jul 19:215829. doi: 10.1016/j.canlet.2022.215829.
    PubMed     Abstract available


    June 2022
  25. CHUA CW, Kruithof-de Julio M
    Featuring the guest editors for the Special Issue on Prostate Cancer, Cancer Letters.
    Cancer Lett. 2022;544:215807.
    PubMed    


  26. MAI CW, Chin KY, Foong LC, Pang KL, et al
    Modeling prostate cancer: What does it take to build an ideal tumor model?
    Cancer Lett. 2022;543:215794.
    PubMed     Abstract available


    May 2022
  27. LORENZONI M, De Felice D, Beccaceci G, Di Donato G, et al
    ETS-related gene (ERG) undermines genome stability in mouse prostate progenitors via Gsk3beta dependent Nkx3.1 degradation.
    Cancer Lett. 2022;534:215612.
    PubMed     Abstract available


    April 2022
  28. PAPACHRISTODOULOU A, Abate-Shen C
    Precision intervention for prostate cancer: Re-evaluating who is at risk.
    Cancer Lett. 2022 Apr 28:215709. doi: 10.1016/j.canlet.2022.215709.
    PubMed     Abstract available


    March 2022
  29. FONTANA F, Anselmi M, Limonta P
    Molecular mechanisms and genetic alterations in prostate cancer: From diagnosis to targeted therapy.
    Cancer Lett. 2022 Mar 8:215619. doi: 10.1016/j.canlet.2022.215619.
    PubMed     Abstract available


    February 2022
  30. DENG W, Zhou X, Zhu K, Chen R, et al
    Novel circular RNA circ_0086722 drives tumor progression by regulating the miR-339-5p/STAT5A axis in prostate cancer.
    Cancer Lett. 2022;533:215606.
    PubMed     Abstract available


  31. MIRO C, Di Giovanni A, Murolo M, Cicatiello AG, et al
    Thyroid hormone and androgen signals mutually interplay and enhance inflammation and tumorigenic activation of tumor microenvironment in prostate cancer.
    Cancer Lett. 2022 Feb 5:215581. doi: 10.1016/j.canlet.2022.215581.
    PubMed     Abstract available


  32. LOWDER D, Rizwan K, McColl C, Paparella A, et al
    Racial disparities in prostate cancer: A complex interplay between socioeconomic inequities and genomics.
    Cancer Lett. 2022 Feb 2. pii: S0304-3835(22)00044.
    PubMed     Abstract available


  33. CHEN H, Miao Y, Bian A, Ye J, et al
    A novel small-molecule activator of unfolded protein response suppresses castration-resistant prostate cancer growth.
    Cancer Lett. 2022;532:215580.
    PubMed     Abstract available


    January 2022
  34. BAEK DS, Kim YJ, Vergara S, Conard A, et al
    A highly-specific fully-human antibody and CAR-T cells targeting CD66e/CEACAM5 are cytotoxic for CD66e-expressing cancer cells in vitro and in vivo.
    Cancer Lett. 2022;525:97-107.
    PubMed     Abstract available


  35. CROWLEY L, Shen MM
    Heterogeneity and complexity of the prostate epithelium: New findings from single-cell RNA sequencing studies.
    Cancer Lett. 2022;525:108-114.
    PubMed     Abstract available


  36. CHALLASIVAKANAKA S, Vickman RE, Kakarla M, Hayward SW, et al
    Fibroblast heterogeneity in prostate carcinogenesis.
    Cancer Lett. 2022;525:76-83.
    PubMed     Abstract available


  37. KANG J, La Manna F, Bonollo F, Sampson N, et al
    Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer.
    Cancer Lett. 2022 Jan 17. pii: S0304-3835(22)00023.
    PubMed     Abstract available


  38. QIAN C, Li D, Chen Y
    ETS factors in prostate cancer.
    Cancer Lett. 2022 Jan 13. pii: S0304-3835(22)00017.
    PubMed     Abstract available


  39. HERNANDEZ I, Cohen M
    Linking cell-surface GRP78 to cancer: From basic research to clinical value of GRP78 antibodies.
    Cancer Lett. 2022;524:1-14.
    PubMed     Abstract available


    December 2021
  40. BERNASOCCHI T, Theurillat JP
    SPOP-mutant prostate cancer: Translating fundamental biology into patient care.
    Cancer Lett. 2021;529:11-18.
    PubMed     Abstract available


  41. MARHOLD M, Kramer G, Krainer M, Le Magnen C, et al
    The prostate cancer landscape in Europe: Current challenges, future opportunities.
    Cancer Lett. 2021 Dec 1. pii: S0304-3835(21)00606.
    PubMed     Abstract available


  42. CHIODELLI P, Coltrini D, Turati M, Cerasuolo M, et al
    FGFR blockade by pemigatinib treats naive and castration resistant prostate cancer.
    Cancer Lett. 2021;526:217-224.
    PubMed     Abstract available


  43. CHAKRABORTY S, Utter MB, Frias MA, Foster DA, et al
    Cancer cells with defective RB and CDKN2A are resistant to the apoptotic effects of rapamycin.
    Cancer Lett. 2021;522:164-170.
    PubMed     Abstract available


    November 2021
  44. SHI M, Wang Y, Lin D, Wang Y, et al
    Patient-derived xenograft models of neuroendocrine prostate cancer.
    Cancer Lett. 2021;525:160-169.
    PubMed     Abstract available


  45. SU S, Cao J, Meng X, Liu R, et al
    Enzalutamide-induced and PTH1R-mediated TGFBR2 degradation in osteoblasts confers resistance in prostate cancer bone metastases.
    Cancer Lett. 2021 Nov 6. pii: S0304-3835(21)00558.
    PubMed     Abstract available


  46. HAQ S, Sarodaya N, Karapurkar JK, Suresh B, et al
    CYLD destabilizes NoxO1 protein by promoting ubiquitination and regulates prostate cancer progression.
    Cancer Lett. 2021;525:146-157.
    PubMed     Abstract available


    October 2021
  47. WANG C, Zhang Y, Gao WQ
    The evolving role of immune cells in prostate cancer.
    Cancer Lett. 2021 Oct 26. pii: S0304-3835(21)00545.
    PubMed     Abstract available


  48. FLORES-TELLEZ TDNJ, Baena E
    Experimental challenges to modeling prostate cancer heterogeneity.
    Cancer Lett. 2021;524:194-205.
    PubMed     Abstract available


  49. TOIVANEN R, Porter LH, Li Z, Clouston D, et al
    Hidden clues in prostate cancer - Lessons learned from clinical and pre-clinical approaches on diagnosis and risk stratification.
    Cancer Lett. 2021;524:182-192.
    PubMed     Abstract available


  50. WANG S, Chao F, Zhang C, Han D, et al
    Circular RNA circPFKP promotes cell proliferation by activating IMPDH2 in prostate cancer.
    Cancer Lett. 2021;524:109-120.
    PubMed     Abstract available


  51. MUGONI V, Ciani Y, Nardella C, Demichelis F, et al
    Circulating RNAs in prostate cancer patients.
    Cancer Lett. 2021;524:57-69.
    PubMed     Abstract available


  52. CACKOWSKI FC, Heath EI
    Prostate cancer dormancy and recurrence.
    Cancer Lett. 2021 Oct 5. pii: S0304-3835(21)00498.
    PubMed     Abstract available


  53. KANAGASABAI T, Li G, Shen TH, Gladoun N, et al
    MicroRNA-21 deficiency suppresses prostate cancer progression through downregulation of the IRS1-SREBP-1 signaling pathway.
    Cancer Lett. 2021 Oct 2. pii: S0304-3835(21)00502.
    PubMed     Abstract available


    September 2021
  54. TIAN P, Zhong M, Wei GH
    Mechanistic insights into genetic susceptibility to prostate cancer.
    Cancer Lett. 2021 Sep 21. pii: S0304-3835(21)00472.
    PubMed     Abstract available


  55. RUIZ DE PORRAS V, Font A, Aytes A
    Chemotherapy in metastatic castration-resistant prostate cancer: Current scenario and future perspectives.
    Cancer Lett. 2021 Sep 10. pii: S0304-3835(21)00430.
    PubMed     Abstract available


    August 2021
  56. WANG Y, Yu J
    Dissecting multiple roles of SUMOylation in prostate cancer.
    Cancer Lett. 2021;521:88-97.
    PubMed     Abstract available


  57. LI Q, Ye L, Zhang X, Wang M, et al
    Corrigendum to "FZD8, a target of p53, promotes bone metastasis in prostate cancer by activating canonical Wnt/beta-catenin signaling" [Cancer Lett. 402 (2017) 166-176].
    Cancer Lett. 2021 Aug 3. pii: S0304-3835(21)00383.
    PubMed    


    July 2021
  58. CAMPBELL KJ, Leung HY
    Evasion of cell death: A contributory factor in prostate cancer development and treatment resistance.
    Cancer Lett. 2021 Jul 31. pii: S0304-3835(21)00378.
    PubMed     Abstract available


  59. GAO Y, Liu Y, Liu Y, Peng Y, et al
    UHRF1 promotes androgen receptor-regulated CDC6 transcription and anti-androgen receptor drug resistance in prostate cancer through KDM4C-Mediated chromatin modifications.
    Cancer Lett. 2021;520:172-183.
    PubMed     Abstract available


  60. LIANG J, Wang L, Poluben L, Nouri M, et al
    Androgen receptor splice variant 7 functions independently of the full length receptor in prostate cancer cells.
    Cancer Lett. 2021 Jul 10. pii: S0304-3835(21)00340.
    PubMed     Abstract available


    June 2021
  61. YAMADA Y, Beltran H
    The treatment landscape of metastatic prostate cancer.
    Cancer Lett. 2021 Jun 18. pii: S0304-3835(21)00295.
    PubMed     Abstract available


  62. JAMROZE A, Chatta G, Tang DG
    Androgen receptor (AR) heterogeneity in prostate cancer and therapy resistance.
    Cancer Lett. 2021;518:1-9.
    PubMed     Abstract available


    May 2021
  63. HOU Z, Huang S, Li Z
    Androgens in prostate cancer: A tale that never ends.
    Cancer Lett. 2021;516:1-12.
    PubMed     Abstract available


  64. FREELAND J, Crowell PD, Giafaglione JM, Boutros PC, et al
    Aging of the progenitor cells that initiate prostate cancer.
    Cancer Lett. 2021;515:28-35.
    PubMed     Abstract available


  65. HUANG SB, Thapa D, Munoz AR, Hussain SS, et al
    Androgen deprivation-induced elevated nuclear SIRT1 promotes prostate tumor cell survival by reactivation of AR signaling.
    Cancer Lett. 2021;505:24-36.
    PubMed     Abstract available


    February 2021
  66. LLOPIZ D, Ruiz M, Silva L, Reparaz D, et al
    Inhibition of adjuvant-induced TAM receptors potentiates cancer vaccine immunogenicity and therapeutic efficacy.
    Cancer Lett. 2021;499:279-289.
    PubMed     Abstract available


    January 2021
  67. SONG J, Yu J, Jeong LS, Lee SK, et al
    A Novel cytarabine analog evokes synthetic lethality by targeting MK2 in p53-deficient cancer cells.
    Cancer Lett. 2021;497:54-65.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.